BETA BIONICS INC (BBNX) Fundamental Analysis & Valuation

NASDAQ:BBNX • US08659B1026

Current stock price

10.95 USD
-0.22 (-1.97%)
Last:

This BBNX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BBNX Profitability Analysis

1.1 Basic Checks

  • BBNX had negative earnings in the past year.
  • In the past year BBNX has reported a negative cash flow from operations.
BBNX Yearly Net Income VS EBIT VS OCF VS FCFBBNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • BBNX's Return On Assets of -21.82% is in line compared to the rest of the industry. BBNX outperforms 47.59% of its industry peers.
  • BBNX has a Return On Equity (-24.49%) which is in line with its industry peers.
Industry RankSector Rank
ROA -21.82%
ROE -24.49%
ROIC N/A
ROA(3y)-32.98%
ROA(5y)N/A
ROE(3y)-57.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBNX Yearly ROA, ROE, ROICBBNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • With a Gross Margin value of 57.15%, BBNX perfoms like the industry average, outperforming 56.15% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for BBNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBNX Yearly Profit, Operating, Gross MarginsBBNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BBNX Health Analysis

2.1 Basic Checks

  • BBNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BBNX has more shares outstanding
  • BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBNX Yearly Shares OutstandingBBNX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M 40M
BBNX Yearly Total Debt VS Total AssetsBBNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • BBNX has an Altman-Z score of 7.61. This indicates that BBNX is financially healthy and has little risk of bankruptcy at the moment.
  • BBNX has a Altman-Z score of 7.61. This is amongst the best in the industry. BBNX outperforms 82.35% of its industry peers.
  • There is no outstanding debt for BBNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.61
ROIC/WACCN/A
WACC8.95%
BBNX Yearly LT Debt VS Equity VS FCFBBNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 10.69 indicates that BBNX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 10.69, BBNX belongs to the best of the industry, outperforming 95.72% of the companies in the same industry.
  • A Quick Ratio of 9.67 indicates that BBNX has no problem at all paying its short term obligations.
  • The Quick ratio of BBNX (9.67) is better than 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 10.69
Quick Ratio 9.67
BBNX Yearly Current Assets VS Current LiabilitesBBNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BBNX Growth Analysis

3.1 Past

  • The earnings per share for BBNX have decreased strongly by -41.37% in the last year.
  • Looking at the last year, BBNX shows a very strong growth in Revenue. The Revenue has grown by 53.94%.
  • The Revenue has been growing by 724.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-41.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.31%
Revenue 1Y (TTM)53.94%
Revenue growth 3Y724.29%
Revenue growth 5YN/A
Sales Q2Q%56.64%

3.2 Future

  • Based on estimates for the next years, BBNX will show a small growth in Earnings Per Share. The EPS will grow by 4.09% on average per year.
  • Based on estimates for the next years, BBNX will show a very strong growth in Revenue. The Revenue will grow by 36.27% on average per year.
EPS Next Y-0.59%
EPS Next 2Y-0.56%
EPS Next 3Y9.49%
EPS Next 5Y4.09%
Revenue Next Year34.67%
Revenue Next 2Y34.65%
Revenue Next 3Y36.48%
Revenue Next 5Y36.27%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BBNX Yearly Revenue VS EstimatesBBNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BBNX Yearly EPS VS EstimatesBBNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. BBNX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BBNX. In the last year negative earnings were reported.
  • Also next year BBNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBNX Price Earnings VS Forward Price EarningsBBNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBNX Per share dataBBNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.56%
EPS Next 3Y9.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BBNX Dividend Analysis

5.1 Amount

  • No dividends for BBNX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BBNX Fundamentals: All Metrics, Ratios and Statistics

BETA BIONICS INC

NASDAQ:BBNX (4/27/2026, 11:36:01 AM)

10.95

-0.22 (-1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-21
Earnings (Next)07-27
Inst Owners108.29%
Inst Owner Change-0.31%
Ins Owners2.39%
Ins Owner Change15.6%
Market Cap487.93M
Revenue(TTM)110.24M
Net Income(TTM)-66.44M
Analysts82.22
Price Target23.63 (115.8%)
Short Float %17.79%
Short Ratio6.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.62%
Min EPS beat(2)1.68%
Max EPS beat(2)31.57%
EPS beat(4)4
Avg EPS beat(4)18.38%
Min EPS beat(4)1.68%
Max EPS beat(4)31.57%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.29%
Min Revenue beat(2)0.46%
Max Revenue beat(2)4.13%
Revenue beat(4)4
Avg Revenue beat(4)7.95%
Min Revenue beat(4)0.46%
Max Revenue beat(4)15.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.84%
PT rev (3m)-28.94%
EPS NQ rev (1m)-3.04%
EPS NQ rev (3m)-3.1%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-7%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)-2.21%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.43
P/FCF N/A
P/OCF N/A
P/B 1.8
P/tB 1.8
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.96
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS2.47
BVpS6.09
TBVpS6.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -21.82%
ROE -24.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.15%
FCFM N/A
ROA(3y)-32.98%
ROA(5y)N/A
ROE(3y)-57.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 341.83%
Cap/Sales 5.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.69
Quick Ratio 9.67
Altman-Z 7.61
F-Score4
WACC8.95%
ROIC/WACCN/A
Cap/Depr(3y)221.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.31%
EPS Next Y-0.59%
EPS Next 2Y-0.56%
EPS Next 3Y9.49%
EPS Next 5Y4.09%
Revenue 1Y (TTM)53.94%
Revenue growth 3Y724.29%
Revenue growth 5YN/A
Sales Q2Q%56.64%
Revenue Next Year34.67%
Revenue Next 2Y34.65%
Revenue Next 3Y36.48%
Revenue Next 5Y36.27%
EBIT growth 1Y-58.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.3%
EBIT Next 3Y13.38%
EBIT Next 5Y13.25%
FCF growth 1Y-8.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.49%
OCF growth 3YN/A
OCF growth 5YN/A

BETA BIONICS INC / BBNX Fundamental Analysis FAQ

What is the fundamental rating for BBNX stock?

ChartMill assigns a fundamental rating of 4 / 10 to BBNX.


What is the valuation status of BETA BIONICS INC (BBNX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BETA BIONICS INC (BBNX). This can be considered as Overvalued.


How profitable is BETA BIONICS INC (BBNX) stock?

BETA BIONICS INC (BBNX) has a profitability rating of 1 / 10.